Douglas R Rank

Summary

Publications

  1. doi request reprint Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia
    Douglas R Rank
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 66:iii53-9. 2011
  2. pmc CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections
    H David Friedland
    Cerexa, Inc, Oakland, California, USA
    Antimicrob Agents Chemother 56:2231-6. 2012

Collaborators

  • H David Friedland
  • Gary W Witherell
  • Alex Smith
  • Joseph B Laudano
  • Donald Biek
  • Paul B Eckburg
  • Tanya O'Neal
  • Lily Llorens
  • Dirk Thye

Detail Information

Publications2

  1. doi request reprint Integrated safety summary of FOCUS 1 and FOCUS 2 trials: Phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia
    Douglas R Rank
    Cerexa, Inc, Oakland, CA 94612, USA
    J Antimicrob Chemother 66:iii53-9. 2011
    ..This report provides an integrated safety summary of the ceFtarOline Community-acquired pneUmonia trial versuS ceftriaxone (FOCUS) 1 and 2 trials (registration numbers: NCT00621504 and NCT00509106)...
  2. pmc CANVAS 1 and 2: analysis of clinical response at day 3 in two phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections
    H David Friedland
    Cerexa, Inc, Oakland, California, USA
    Antimicrob Agents Chemother 56:2231-6. 2012
    ..7% and 77.4% in the ceftaroline and V/A groups, respectively. In this retrospective analysis, ceftaroline fosamil monotherapy had a numerically higher clinical response than V/A at day 3 in the treatment of ABSSSI...